SCHEMBL18869413

SCHEMBL18869413

Cc1sc2cccc(Cl)c2c1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.53
MCL1 Q07820 3/20 0.53
OGG1 O15527 1/20 0.47
MAPT P10636 3/20 0.46
ALDH1A1 P00352 7/20 0.45
KDM4E B2RXH2 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 5/20 0.38
USP2 O75604 1/20 0.38
TSHR P16473 1/20 0.38
PSMB8 P28062 2/20 0.36
PDE10A Q9Y233 1/20 0.36
HPGD P15428 2/20 0.36
GAA P10253 1/20 0.33
PKM P14618 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
ADRB2 P07550 1/20 0.33
ADRB1 P08588 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14154413 0.83 MAPK1 (0.37) MAPK1MCL1OGG1MAPTALDH1A1
SCHEMBL12693662 0.80 ALDH1A1 (0.45) MAPK1MCL1OGG1MAPTALDH1A1
SCHEMBL31568860 0.77 MAPK1 (0.53) MAPK1MCL1OGG1MAPTALDH1A1
SCHEMBL9616024 0.75 MAPK1 (0.62) MAPK1MCL1OGG1MAPTALDH1A1
SCHEMBL18858491 0.75 MAPK1 (0.49) MAPK1MCL1OGG1MAPTALDH1A1
SCHEMBL19134581 0.75 MAPK1 (0.49) MAPK1MCL1OGG1MAPTALDH1A1
SCHEMBL12680456 0.72 PIM1 (0.32)
SCHEMBL13946722 0.71 MAPK1 (0.53) MAPK1MCL1OGG1MAPTALDH1A1
SCHEMBL154877 0.70 LOXL2 (0.53) MCL1OGG1MAPTALDH1A1KDM4E
SCHEMBL1520807 0.69 MCL1 (1.00) MAPK1MCL1OGG1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3154973-B1 TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL MYERS SQUIBB CO (US) 2018-03-21 EP disclosed
US-9708323-B2 Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands BRISTOL-MYERS SQUIBB COMPANY (US) 2017-07-18 US disclosed
US-20170137425-A1 TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL MYERS SQUIBB CO (US) 2017-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170137425-A1 TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA6, CHRNA5 MAPK1 2047/4885MCL1 4410/4885OGG1 1852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.